Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. The company’s primary product is PEMGARDA (pemivibart), a half-life extended monoclonal antibody authorized for the pre-exposure prophylaxis of COVID-19 in immunocompromised adults and adolescents. Its pipeline includes VYD2311, a next-generation monoclonal antibody candidate for COVID-19 prevention currently in Phase 3 clinical trials, and VBY329, a candidate for the prevention of respiratory syncytial virus infections in neonates and children. Invivyd also investigates monoclonal antibodies for measles and other high-need indications. The company utilizes a proprietary technology platform for viral surveillance and antibody engineering, partnering with Adimab for platform technology and WuXi Biologics for manufacturing and development activities.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage invivyd.com
Sector Healthcare IR page investors.invivyd.com
Tags
monoclonal antibodies, infectious diseases, viral prophylaxis, sars-cov-2, rsv, measles, antibody engineering, immunocompromised patients, PEMGARDA, pemivibart, VYD2311, adintrevimab, VBY329, Adimab, WuXi Biologics, SPEAR Study Group, REVOLUTION, DECLARATION, LIBERTY
Press page —

Metrics

Valuation  
Market cap $ 257.23M
Market cap (USD) $ 257.23M
P/E -2.49
PEG —
P/BV 1.71
P/S 4.24
P/OCF -1.94
P/FCF -1.92
Dividend yield —
Turnover / mcap —
Returns  
ROE -34.0%
ROI -327.4%
ROIC -259.9%
Profit margin -98.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 60
Quality score -25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 53.426M 25.384M — — — —
Net profit -52.489M -169.925M -198.643M -241.317M -226.79M —
Free cash flow -58.29M -170.631M -173.779M -221.692M -184.82M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.47 0.44 3.94 1.5 7.26 —
Price performance 12m 4.57 -0.89 1.63 -0.79 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 0.00 10.9M 13.9M
↳ YoY growth +27.6%
Lease liabilities (USD) — 0.00 3.72M 2.17M 1.3M 2.49M
Cash and deposits (USD) 115M 542M 92.1M 201M 69.3M 227M
Right-of-use assets (USD) — 0.00 3.78M 2.23M 1.39M 2.44M
Cash flow detail
Operating cash flow (USD) — -185M -220M -173M -170M -58.1M
Purchases of property, plant and equipment (USD) — -84,000 -1.71M -615,000 -140,000 -155,000
Change in receivables (cash effect) (USD) — — — 0.00 -10.9M -3.34M
Change in inventories (cash effect) (USD) — — — 0.00 -24.9M -373,000
Change in payables (cash effect) (USD) — -2.37M -4.3M 6.47M 2.42M 3.21M
Share buybacks (cash effect) (USD) — 0.00 -4,000 -1,000 0.00 —
Share-based compensation (USD) — 17.8M 21.6M 18.7M 19.8M 11.6M
Operating cash flow before change in receivables (USD) — — — -173M -160M -54.8M
Free cash flow (OCF - PPE - intangibles) (USD) — -185M -222M -174M -171M -58.3M
Income detail
Research and development expense (USD) — 183M 179M 159M 137M 38.3M
Total comprehensive income (USD) — -227M -242M -198M -170M -52.5M
Comprehensive income to owners (USD) — -227M -242M -198M -170M -52.5M
Reported Sep 20, 2021 May 13, 2022 Mar 23, 2023 Mar 20, 2025 Mar 20, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Results of Operations and Financial Condition.

On November 16, 2026, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026, and recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.

October 21, 2026

PDF Version

  • VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd

  • VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for both treatment and prevention of measles

  • Invivyd is scaling up production toward clinical development in 2027

  • There are currently no FDA approved treatments for measles, leaving a major gap in the public health and medical management of measles

  • The U.S. is experiencing a record-breaking number of measles cases in 2026, and a significant immunity gap has emerged, leaving millions of Americans vulnerable to measles infection and associated complications

NEW HAVEN, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the presentation of preclinical data describing its novel, potential first- and best-in-class investigational monoclonal antibody candidate VMS063 at IDWeek 2026™ in Washington, D.C. Data demonstrated highly potent in vitro antiviral activity against contemporary measles fusion protein (MeV-F) variants, supporting its potential utility for both treatment and prevention (pre/post-exposure prophylaxis) of measles.

VMS063 is a highly potent, half-life-extended, high resistance barrier measles monoclonal antibody candidate engineered via Invivyd’s proprietary antibody discovery platform to target a highly conserved protein of measles virus. VMS063 could be the first precision therapy for measles, as well as a potentially important direct immunization option to supplement, offer an alternative to, or enhance standard measles vaccination. As a potential measles prophylactic option, Invivyd intends to maximize the convenience of accessing antibody immunization versus measles virus by developing VMS063 in either intramuscular or subcutaneous forms. Invivyd has begun manufacturing scale-up toward clinical development in 2027.

“Despite continued transmission of measles globally, and a reemergence in the United States, physicians who see measles patients have long lamented that there are no targeted approved treatments for measles. More generally, there has been little, if any, innovation in how we prevent and treat measles since 1963. As we see more and more cases, it’s clear that Americans, as well as the international community, need additional prevention options for measles as well as a specific treatment,” said Michael Mina, M.D., Ph.D., Chief Medical Officer and Chief Epidemiologist of Invivyd and widely cited measles researcher. “A molecule like VMS063 has the potential to transform the measles landscape by leveraging the extraordinary potential of monoclonal antibodies that can, with one molecule, provide both prevention and treatment to fill these gaps. We are excited to interact with the scientific and public health community at IDWeek 2026™, as well as leaders across public health more generally, and we are rapidly advancing this program toward clinical development.”

At IDWeek 2026™, Invivyd will present data describing that VMS063 binds a highly conserved epitope of the MeV-F protein, stabilizing its pre-fusion conformation, supporting a mechanism of neutralization through inhibition of membrane fusion. Invivyd characterized the properties of VMS063 including its highly potent in vitro neutralization activity against historical and contemporary MeV variants, including the highest circulating contemporary genotypes, B3 and D8, in both authentic virus and pseudovirus neutralization assays.

The United States is facing a critical measles virus inflection point in 2026, with measles incidence reaching levels not seen in decades. As of October 2026, U.S. disease burden is nearly double that seen in 2025. As pediatric and community vaccination rates dip, a significant immunity gap has emerged. More than nine million school-aged children are estimated to be unprotected against measles in the U.S. today along with many millions more adults who are immune compromised. More, as one of the most infectious viruses known to exist, and a virus uniquely capable of destroying human immunologic memory, measles has the potential to impose a substantial burden on the healthcare system as infection spreads.

IDWeek 2026™ is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2026™ takes place Oct. 21-24 at the Walter E. Washington Convention Center (801 Allen Y. Lew Place NW) in Washington, D.C. For more information, visit www.idweek.org.

About VMS063 VMS063 is a novel, highly potent, half-life-extended, high resistance barrier measles monoclonal antibody candidate engineered via Invivyd’s proprietary antibody discovery platform to target a highly conserved protein of measles virus. VMS063 targets the measles Fusion (F) protein and is designed to lock the trimeric measles Fusion protein into a pre-fusion configuration, thereby preventing cell entry, similar to approved pediatric respiratory syncytial virus (RSV) monoclonal antibodies. VMS063 could be the first precision therapy for measles, as well as a potentially important passive preventive option to supplement or enhance measles vaccination.

About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Trademarks are the property of their respective owners.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “estimates,” “future,” “intends,” “plans,” “potential,” “predicts,” “projects,” and “targets” or similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, plans related to the company’s measles program, and the potential of VMS063 as a novel, potential first- and best-in-class mAb candidate being developed for the treatment and prevention of measles; the potential for VMS063 to be the first precision therapy for measles and a potentially important direct immunization option to supplement, offer an alternative to, or enhance standard measles vaccination; the company’s anticipated development and clinical timeline for VMS063; expectations regarding the public health environment and potential of a molecule like VMS063 to transform the measles landscape; the company’s plans to develop VMS063 in either intramuscular or subcutaneous forms; the company’s strategies and objectives; the company’s future prospects; and other statements that are not historical fact. The company may not actually achieve the plans, intentions, or expectations disclosed in the company’s forward-looking statements, and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress, and results of the company’s discovery and preclinical development activities, including with respect to VMS063; whether or not any preclinical candidate identified by the company is determined to be suitable for clinical development; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company’s product candidates based on neutralizing activity in nonclinical studies and the assessment of other in vitro properties; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; the company’s reliance on third parties; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; changes in the regulatory environment; the risk that a lack of awareness of mAb therapies and regulatory scrutiny of mAb therapies may adversely impact the development or commercial success of the company’s product candidates; changes in expected or existing competition; the company’s reliance on third parties; complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, each as filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

October 14, 2026

PDF Version

  • FLINTLOCK Phase 2 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in adults aged 18-65 years with Long COVID or Post-Vaccination Syndrome, also known as COVID vaccine injury

  • Design includes VYD2311 administered in three doses to assess the safety and potential clinical benefit of VYD2311 treatment versus placebo over 90 days

  • VYD2311 has demonstrated high in vitro antiviral potency across all SARS-CoV-2 variants tested from original Wuhan through contemporary Omicron variants

  • FLINTLOCK is part of Invivyd’s broader REVOLUTION clinical program for VYD2311, including DECLARATION and LIBERTY

  • Millions of individuals continue to live with persistent and debilitating symptoms of Long COVID, underscoring the significant unmet need for development of effective treatment options

NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in individuals with Long COVID or Post-Vaccination Syndrome (PVS), also known as COVID vaccine injury.

“Long COVID continues to be a significant challenge for millions of Americans. It is a disease state characterized by persistent and debilitating symptoms impacting multiple systems across the human body, including immune dysfunction, cardiovascular issues, respiratory challenges, nervous system dysfunction, pain, and other health issues that can impact a person’s day-to-day life,” noted David Putrino, Ph.D., Nash Family Director of the Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai and Founding Member of the SPEAR Study Group. “We are excited to take the next step in advancing this potential therapeutic option for patients living with Long COVID or Post-Vaccination Syndrome, a diagnosis which has received very little attention.”

The Phase 2 FLINTLOCK clinical trial includes the following study features:

  • Randomized, double-blind, placebo-controlled, proof-of-concept study

  • Tests Invivyd’s monoclonal antibody VYD2311, an investigational monoclonal antibody that has been demonstrated to be pharmaceutically active against all SARS-CoV-2 variants tested to date from current variants back to original Wuhan variants

  • High-dose initial intravenous (IV) infusion of VYD2311 followed by monthly intramuscular (IM) injections at days 30 and 60 with total dose targeted at 10x the prophylactic dose of VYD2311 assessed in DECLARATION and LIBERTY, while still below doses already assessed with a positive initial safety profile in VYD2311 first-in-human testing (LINK)

  • Inclusion criteria designed to enroll adults aged 18-65 years with confirmed Long COVID or PVS; criteria include having at least 2 persistent symptoms after a COVID-19 infection or following COVID-19 vaccine injury

  • Clinical efficacy evaluations include functional performance tests consistent across prior studies of Long COVID and other infection-associated chronic conditions and illnesses, through Day 90

  • Assessment of the safety and tolerability of VYD2311 based on the incidence, severity, causality, and outcome of treatment emergent adverse events (TEAEs) and hypersensitivity reactions through Day 90, as well as evaluation of the pharmacokinetics of VYD2311 by measuring serum concentrations through Day 90

  • Initial data expected in mid-2027.

“Both Long COVID and COVID PVS may share the inflammatory presence of persistent SARS-CoV-2 spike protein in the underlying disease processes, and so we are bringing to bear our pharmacology that is specifically directed against the SARS-CoV-2 spike protein target in large quantities,” said Marc Elia, Chairman and CEO of Invivyd. “Previous Long COVID antiviral therapeutic efforts have been limited by use of short course therapies that may not adequately inhibit viral replication, or by the use of monoclonal antibody candidates that lacked activity against many known and circulating clinical variants. However, given anecdotal independent case reports of highly active monoclonal antibodies generating clinical improvements in Long COVID patients, including with our current monoclonal antibody medicine PEMGARDA® (pemivibart), we are looking forward to advancing FLINTLOCK and potentially bringing forward a therapeutic option for the benefit of people suffering from Long COVID.”

Further details on the FLINTLOCK Phase 2 Long COVID trial of VYD2311 will be posted near-term to www.clinicaltrials.gov.

PEMGARDA® (pemivibart) is not authorized or approved for the treatment of Long COVID or PVS.

About VYD2311VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration.

VYD2311 was engineered using Invivyd’s proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. VYD2311 leverages the same antibody backbone as pemivibart, Invivyd’s investigational mAb granted emergency use authorization in the U.S. for the pre-exposure prophylaxis (PrEP) of symptomatic COVID-19 in certain immunocompromised patients, and adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19.

About FLINTLOCKFLINTLOCK is a Phase 2, randomized, double-blind, placebo-controlled, proof-of-concept study is being conducted to investigate the safety, tolerability, pharmacokinetics, clinical activity, immunogenicity, and SARS-CoV-2 neutralizing antibody response of VYD2311. VYD2311 will be administered first as a loading dose via intravenous infusion on Day 1 followed by additional intramuscular injections on Day 30 and Day 60 in adults aged 18-65 years with a confirmed diagnosis of Long COVID or Post-Vaccination Syndrome (PVS), with two or more symptoms, with or without SARS-CoV-2 spike antigen that are present ≥6 months after having a COVID-19 infection or vaccination. Total enrollment of the trial is approximately 130 participants.

About DECLARATIONDECLARATION is a Phase 3, randomized, triple-blind, placebo-controlled trial to evaluate VYD2311 efficacy and safety in prevention of symptomatic COVID in a broad population of participants including adults and adolescents both with and without risk factors for progression to severe COVID-19 at three months. Participants will receive either a single dose or monthly doses of VYD2311, each administered via intramuscular injection, compared to placebo. Total enrollment of the trial is approximately 2,400 participants.

About LIBERTYLIBERTY is a Phase 3, randomized, double-blind study to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and co-administered VYD2311 with an mRNA COVID vaccine. Total enrollment of the trial was approximately 210 participants.

About PEMGARDAPEMGARDA® (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC, LP.8.1 and XFG. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.

PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.

PEMGARDA is not authorized for use for the treatment of COVID-19, Long COVID, or COVID-19 Post-Vaccination Syndrome, or for post-exposure prophylaxis of COVID-19. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccinations, should receive COVID-19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination.

Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse reactions included systemic infusion-related reactions and hypersensitivity reactions, local infusion site reactions, and infusion site infiltration or extravasation. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.

To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based on available information including variant susceptibility to PEMGARDA and national variant frequencies.

The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization revoked sooner. On June 30, 2026, the U.S. Department of Health and Human Services (HHS) announced notice of the termination of the declaration, effective June 29, 2027.

About SPEAR Study Group Invivyd and leading researchers formed the SPEAR (Spike Protein Elimination and Recovery) Study Group to assess the effects of monoclonal antibody (mAb) therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.

About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Trademarks are the property of their respective owners.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “estimates,” “future,” “intends,” “plans,” “potential,” “predicts,” “projects,” and “target” or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, plans related to the company’s research and development activities, and the timing and potential results thereof, including with respect to the FLINTLOCK Phase 2 clinical trial and the broader REVOLUTION clinical program; the potential of mAbs as a therapeutic option for patients living with Long COVID or PVS; the potential of VYD2311 as a novel mAb candidate that may be able to deliver clinically meaningful titer levels through more patient-friendly means; the purpose and goals of the SPEAR Study Group; the company’s strategies and objectives; the company’s future prospects; and other statements that are not historical fact. The company may not actually achieve the plans, intentions, or expectations disclosed in the company’s forward-looking statements, and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress, and results of the company’s discovery, preclinical, and clinical development activities, including the FLINTLOCK Phase 2 clinical trial and the broader REVOLUTION clinical program; clinical trial site activation or enrollment rates; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company’s product candidates based on neutralizing activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that VYD2311 targets remains structurally intact and the company’s product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; whether mAb therapy is able to offer a therapeutic approach for Long COVID or PVS; changes in the regulatory environment; the outcome of the company’s engagement with regulators; uncertainties related to the regulatory approval process, and available development and regulatory pathways; the ability to maintain a continued acceptable safety, tolerability, and efficacy profile of any product candidate following regulatory authorization or approval; the risk that a lack of awareness of mAb therapies and regulatory scrutiny of mAb therapies may adversely impact the development or commercial success of the company’s product candidates; changes in expected or existing competition; the company’s reliance on third parties; complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, each as filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Prompts

Invivyd, Inc. (ticker IVVD), listed in United States.

Company History

Date Change Detail
Sep 13, 2022 Renamed ADAGIO THERAPEUTICS, INC. → INVIVYD, INC.

ETFs Holding Invivyd, Inc.

ETF Weight in ETF Shares Market value As of
RESM 0.01% 292 $ 254.74 Jun 30, 2026